Page last updated: 2024-08-24

plerixafor and abt-199

plerixafor has been researched along with abt-199 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y1
Bouchlaka, MN; Capitini, CM; Cho, MM; Feils, AS; Gavcovich, TB; Hess, NJ; Kabakov, SA; Olson, SL; Quamine, AE; Rinella, SP; Rui, L; Turicek, DP; Walker, KL; Zhu, F1

Reviews

1 review(s) available for plerixafor and abt-199

ArticleYear
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases

2022

Other Studies

1 other study(ies) available for plerixafor and abt-199

ArticleYear
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:5

    Topics: Benzylamines; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Cyclams; Hematopoietic Stem Cell Mobilization; Humans; Janus Kinase 1; Nitriles; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Receptors, CXCR4; Sulfonamides

2021
chemdatabank.com